- Home
- VEL vs FULC Comparison
VEL vs FULC Comparison
Compare VEL & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | FULC |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 768.3M | 707.9M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VEL | FULC |
|---|---|---|
| Price | $19.77 | $10.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $21.75 | $16.38 |
| AVG Volume (30 Days) | 98.6K | ★ 491.9K |
| Earning Date | 05-03-2026 | 04-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.66 | ★ 89.94 |
| EPS | ★ 1.86 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $27.31 | N/A |
| P/E Ratio | $8.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.12 | $2.32 |
| 52 Week High | $21.40 | $15.74 |
Technical Indicators
Market Signals| Indicator | VEL | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 53.78 |
| Support Level | $19.52 | $10.25 |
| Resistance Level | $20.05 | $11.17 |
| Average True Range (ATR) | 0.52 | 0.68 |
| MACD | -0.10 | 0.08 |
| Stochastic Oscillator | 20.20 | 68.58 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.